Oxford Biomedica (LON:OXB) Issues Quarterly Earnings Results

Oxford Biomedica (LON:OXB) released its earnings results on Wednesday. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%.

Oxford Biomedica Stock Up 3.0%

Oxford Biomedica stock traded up GBX 14.24 during midday trading on Thursday, reaching GBX 495.24. The stock had a trading volume of 1,463,605 shares, compared to its average volume of 1,108,665. Oxford Biomedica has a 12 month low of GBX 420 and a 12 month high of GBX 952. The company has a market capitalization of £599.47 million, a P/E ratio of -18.40 and a beta of 1.09. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08. The company has a fifty day moving average price of GBX 512.48 and a two-hundred day moving average price of GBX 576.03.

Analysts Set New Price Targets

Several analysts have issued reports on OXB shares. Royal Bank Of Canada restated an “outperform” rating and issued a GBX 900 price target on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Jefferies Financial Group restated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 595 price target on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.